SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Domenge C, Hill C, Lefebvre J, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer. 2000; 83: 15941598.
  • 2
    Posner M, Colevas A, Tishler R. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol. 2000; 27 (Suppl G): 1324.
  • 3
    Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in Stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del collo. J Natl Cancer Inst. 1994; 86: 265272.
  • 4
    Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324: 16851689.
  • 5
    Spaulding M, Fischer S, Wolf G. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol. 1994; 12: 15921599.
  • 6
    Lefebvre J, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer Phase III trial. J Natl Cancer Inst. 1996; 88 (13): 890898.
  • 7
    Adelstein D, Adams G, Li Y, et al. A Phase III comparison of standard radiation therapy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5-fluorouracil (5FU) in patients with unresectable squamous cell head and neck cancer (SCHNC): an Intergroup study [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 1624.
  • 8
    Adelstein D, Kalish L, Adams G, et al. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol. 1993; 11: 21362142.
  • 9
    Browman G, Cripps C, Hodson D, Eapen L, Sathya J, Levine M. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol. 1994; 12: 26482653.
  • 10
    Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst. 1999; 91: 20812086.
  • 11
    Brizel D, Albers M, Fisher S, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998; 338: 17981804.
  • 12
    Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998; 16: 13181324.
  • 13
    Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy—results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2001; 50: 11611171.
  • 14
    Tishler RB, Busse PM, Norris CM, et al. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys. 1999; 43: 10011008.
  • 15
    Steinberg L, Hassan M, Hoppel C, et al. A Phase I study of radiotherapy and simultaneous paclitaxel in patients with locally advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 1996; 15: 321.
  • 16
    Sunwoo J, Herscher L, Kroog G, et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol. 2001; 19: 800811.
  • 17
    Rosenthal D, Lee J, Sinard R, et al. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2001; 19: 13631373.
  • 18
    Plasswilm L, Kisschner M, Sauer R. Concurent taxol and split-course accelerated radiotherapy for advanced head and neck cancer. Strahlenther Onkol. 1996; 172: 573579.
  • 19
    Machtay M, Aviles V, Kligerman MM, Treat J, Weinstein GS, Weber RS. A Phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy in unresectable head and neck cancer. Int J Radiat Oncol Biol Phys. 1999; 44: 311315.
  • 20
    Hoffmann W, Belka C, Schimdberger H, Budach W, Bochtler H, Fhess CF. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer—results from a Phase I trial. Int J Radiat Oncol Biol Phys. 1997; 38: 691696.
  • 21
    Hesse K, Heinreich B, Zimmerman F, Kau R, Sommer G, Achterrath W. Combined radiochemotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors. Strahlenther Onkol. 2000; 176: 6772.
  • 22
    Dowell JE, Sinard R, Yardley D, et al. Seven-week continuous infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Semin Radiat Oncol. 1999; 9 (Suppl 1): 97101.
  • 23
    Choy H, Akerly W, Safrin H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol. 1994; 12: 26822686.
  • 24
    Glantz M, Choy H, Kearns C, et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial radiation in adults with astrocytomas. J Clin Oncol. 1996; 14: 600609.
  • 25
    Tishler R, Geard C, Hall E, Schiff P. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 1992; 52: 34953497.
  • 26
    Tishler R, Schiff P, Geard C, Hall E. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 1992; 22: 613617.
  • 27
    Liebmann J, Cook J, Fisher J, Teague D, Mitchell J. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 1994; 86: 441446.
  • 28
    Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res. 1996; 56: 51985204.
  • 29
    Mason K, Hunter N, Milas M, Abbruzzese J, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 1997; 12: 24312438.
  • 30
    Joschko M, Webster L, Groves J, Ball D, Bishop J. Radiation enhancement by taxol in squamous carcinoma of the hypopharynx (FaDu) in nude mice. Proc Am Assoc Cancer Res. 1994; 35: 674.
  • 31
    Mote P, Davey M, Davey R, Oliver L. Paclitaxel sensitizes multidrug resistant cells to radiation. Anticancer Drugs. 1996; 7: 182188.
  • 32
    Clark J, Busse P, Norris C, et al. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol. 1997; 15: 31003110.
  • 33
    Colevas A, Norris C, Tishler R, et al. A Phase II trial of TPFL (docetaxel, cisplatin, 5-fluorouracil, leucovorin) as induction for squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 1999; 17: 35033511.
  • 34
    Wahl A, Donaldson K, Fairchild C, et al. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med. 1996; 2: 7279.
  • 35
    Moos P, Fitzpatrick F. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Diff. 1998; 9: 687697.
  • 36
    Milas L, Saito Y, Hunter N, Milross C, Mason K. Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma. Radiother Oncol. 1996; 40: 163167.
  • 37
    Hainsworth J, Burris H, Greco F. Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol. 1999; 26 (Suppl 10): 1924.
  • 38
    Mauer A, Masters G, Haraf D, et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1998; 16: 159164.
  • 39
    Koukourakis M, Bahlitzanakis N, Froudarakis M, Giatromanolaki A, Georgoulias V, Koumiotaki S. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of Stage IIIB non-small-cell lung carcinoma. Br J Cancer. 1999; 80: 17921796.
  • 40
    Dreyfuss A, Clark J, Norris C, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996; 14: 16721678.
  • 41
    Catimel G, Verwij J, Hanauske A. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol. 1994; 5: 553537.
  • 42
    Koukourakis M, Bizakis J, Skoulakis C, Kyrmizakis D, Giatromanolaki A, Papadakis C. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A Phase I dose escalation study. Anticancer Res. 1999; 19: 23052309.
  • 43
    Fu K, Pajak T, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000; 48: 716.